Committed to scientific excellence
Crown Bioscience Inc. leads the field in providing unique translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in dedicated two therapeutic areas: Oncology and Metabolic Disease.
CrownBio has unique assets in oncology. HuPrime® and HuKemia® enable personalized medicine by allowing the biology of disease to be directly assessed and tested in primary patient tumorgraft models enabling phase 0 model selection. CrownBio’s HuBase®: a genomically defined patient derived tumor database of our primary disease models, and our HuMark® predictive biomarker discovery services translate your results into insightful clinical design strategies resulting in more successful clinical trial outcomes. Our newly launched translational services for Metabolic Disease are setting new standards by employing highly translatable disease models and cutting edge genomic tools. Our unique assets, including D*Base and our naturally occurring diabetes non-human primate colonies, are revolutionizing diabetes and obesity research.
CrownBio offers a truly integrated approach to undertaking complete drug discovery programs as well as hit identification, hit-to-lead, and lead optimization projects. Our industry-seasoned, multi-disciplinary research teams work closely with our clients' scientists to enhance knowledge, add manpower, shorten time to development candidate identification, and increase the value of their drug discovery programs. CrownBio's proven track record, moving hits to leads to candidates through our integrated services, enables early and confident selection of robust pre-clinical molecules.
Our company is headquartered in the heart of Silicon Valley, with wholly owned research facilities in Kanapolis, Beijing (China), and Taicang (China). Our state-of-the-art 40,000 and 100,000 sq ft animal vivariums are fully accredited by AAALAC, winning CrownBio an exemplary citation.
